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Abstract
We here report an informative case of severe bleeding diathesis in a patient 
with Chronic Lymphocytic Leukaemia (CLL), due to Acquired Von Willebrand 
Syndrome (AVWS) and impaired platelets aggregation under the treatment with 
Ibrutinib.
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Introduction
The diagnosis of Acquired Von Willebrand Syndrome (AVWS) 
might be challenging because of the broad spectrum of its clinical 
and laboratory features. The AVWS is a rare bleeding disorder caused 
by a structural or functional defect in von Willebrand Factor (vWF) 
that can be associated with autoimmune conditions, neoplasia, 
lymphoproliferative, myeloproliferative and cardiovascular disorders 
[1,2]. A variety of pathogenic mechanisms have been described, and 
include the formation of antibodies to the von Willebrand Factor 
(vWF) (antibodies to vWF are shown in vitro in only a minority of 
the cases), its absorption from the surfaces of transformed cells or 
platelets and its mechanical destruction under the shear-stress [3]. 
The bleeding history is usually characterized by spontaneous 
mucocutaneous and/or gastrointestinal haemorrhage, occurring 
in patients without a family history of bleeding disorders [4]. The 
diagnosis is based on the detection of low of a plasma concentration 
or impaired activity of vWF [5].
Bruton Tyrosine Kinase (BTK) functions downstream of multiple 
surface receptors in hematopoietic cells. Its constant activation via 
B-cell antigen receptor signalling in various B-cell malignancies leads 
to downstream activation of essential cell survival pathways such as 
NF-B and MAPK [6,7]. Reversible inhibition of BTK by Ibrutinib 
disrupts proliferation, differentiation and migration of normal and 
malignant B-cells, rendering it an effective therapeutic agent in 
B-cells neoplasms [8-10].
BTK activation via several platelet transmembrane receptors, 
including the platelet collagen receptor glycoprotein VI is required 
for a normal platelet activation. BTK blockage by Ibrutinib also 
leads to an impaired platelets aggregation, and can cause a severe 
hemorrhagic diathesis, including subdural hematomas and 
gastrointestinal bleedings [6,11-15]. Additionally, in vitro and in vivo 
studies show that Ibrutinib can affect platelet adhesion to the vWF via 
inhibition of the GPIb-receptor signaling [16,17]. 
We here describe the case of patient with Chronic Lymphocytic 
Leukaemia (CLL) that presented with both, a severe persistent 
hemorrhagic diathesis due to the combination of an AVWS as well 
as an impaired platelets function under the treatment with Ibrutinib.
Case Description
65-year old male patient with a past medical history of arterial 
hypertension and a Deep Vein Thrombosis (DVT) on the left low 
extremity presented in October 2012 with constitutional symptoms, 
generalized lymphadenopathy and lymphocytic leucocytosis.
Immunophenotyping of peripheral blood lymphocytes by flow 
cytometry and immunohistochemistry on a bone marrow biopsy 
reveal a typical B-CLL phenotype: CD5+, CD23+, CD20weak, and 
FMC7 and Cyclin D1 negativity. Investigations revealed a Binet B and 
Rai I. Neither cytogenetic nor molecular (mutation TP53) analysis 
is available as this was not routinely performed at the time in the 
external hospital.
The patient received six cycles of Rituximab/Bendamustin as a first 
line treatment, and achieved a good partial remission. Seven months 
later, he presented with new and significant B-symptoms. Richter’s 
transformation to Diffuse Large B-Cell Lymphoma (DLBCL) was 
excluded by a repeated lymph node biopsy. R-CHOP to treat this early 
progression lead to a minor response only. Treatment intensification 
was initiated with O-DHAP. Unfortunately, autologous stem cell 
collection with Navelbine failed.
Response after this treatment lasted only a couple of weeks, and 
the patient again presented with progressive disease with generalized 
lymphadenopathy and anemia (Hb 90-110g/l, thrombocytes 150-
200G/l). A treatment therapy with Ibrutinib was started. This resulted 
in a partial remission, as confirmed by CT-scan two months after 
treatment initiation. A dose reduction to 140 mg/day was needed due 
to grade 3 diarrhoea.
Furthermore, recurrent muco-cutaneous bleedings, rated 
by 9 points according to the ISTH-Bleeding-score standardized 
questionnaire occurred. The platelet number was normal at that time. 
The coagulation tests revealed the only mild aPTT (activated Partial 
Thromboplastin Time) prolongation (44sec). Further investigation 
showed normal values of Fibrinogen, Factor II, V, VII, IX, XI and 
XII. However, both the vWF and VIII-factor activities were reduced 
to 35% and 44%, respectively, in this patient with of 0 (Rh+) blood 
group.
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The advanced platelet function analysis showed prolonged closure 
time with both collagen and epinephrine. The platelet aggregation 
test revealed an impaired platelet aggregation in response to collagen 
and a Ristocetin test revealed a biphasic platelet activation curve. The 
normal platelet aggregation could be restored in presence of ADP and 
arachidonic acid. Altogether, the findings were consistent with the 
diagnosis of an AVWS.
He experienced a severe epistaxis in August 2015. Emergency 
embolization of the A. maxillaris bilateralis was needed. Imaging 
revealed an epipharyngeal mass as a possible source of the bleeding, 
a biopsy showed an infiltration by the small lymphocytic lymphoma. 
Radiation therapy with 20Gy was given to the nasopharyngeal cavity.
Due to progressive disease, Ibrutinib was stopped in August 
2015. The bleeding tendency, however, persisted, and therapy with 
the PIK3A inhibitor Idealisib was initiated.
Repetitive hemostasis tests showed a progressive decline of the 
von Willebrand factor and factor VIII:C. The clearance test of vWF 
clearly shows a higher activity of 72% after the Haemate substitution 
(Table 1). 
Two months after the initiation of Idelalisib therapy, the patient 
presented a severe mucositis. He also developed a significant and 
further deterioration of his performance status. A CT-scan confirmed 
a further disease progression, and the patient died shortly after. 
Discussion
This patient’s history is informative as it includes a multifactorial 
aetiology of persistent severe bleeding diathesis and illustrates a 
possible therapeutic dilemma when treating such patients.
The AVWS was of origin of the disease-related hemostatic 
failure in this patient. The main supposed mechanism in CLL is a 
destruction of vWF by autoantibodies that are secreted by malignant 
B-lymphocytes [2]. The treatment approach here is based on the 
malignant clone eradication. Since CLL in our case was primary 
resistant, the hemorrhagic diathesis due to the vWF exhaustion 
correlated positively with the disease progression.
The second mechanism that played an important role in the 
bleeding persistence in our case was the qualitative (thrombopenia) 
and quantitative (impaired aggregation) platelet function 
perturbation.
The defective platelet aggregation was a manifestation of AVWS, 
and a consequence of inhibition of platelets signal transduction 
by Ibrutinib. Since the BTK-inhibitor can influence the platelet 
activation via blockage of vWF/GPIb‐IX‐V signalling, the platelet 
aggregation assay was not specific enough to distinguishing AVWS- 
from Ibrutinib-mediated platelets function perturbation.
The PIK3A-inhibitor Idealisib could apparently ameliorate 
platelet function in patients with CLL, as it was shown by platelet 
aggregation essay [18].
In our case, we did not observe any improvement in the bleeding 
syndrome after Idealisib introduction. We believe that it could be 
explained by concomitant progressive AVWS, which levelled all 
possible positive effects of Idealisib on platelet aggregation. Moreover, 
and with regard to the bleeding problems, Idealisib was probably 
introduced too late, already in setting of a highly resistant disease 
associated with severe secondary thrombopenia. An earlier switch 
from Ibrutinib to Idealisib could probably have been a better strategy, 
at least for bleeding symptoms improvement. 
Concerning the possible approach to the underlying progressive 
AVWS, Intravenous Immune Globulins (IVIG) could also have been 
an option as previously shown, especially in the cases with anti-vWF 
autoantibodies. The IVIG association with AVW concentrates may 
be even more beneficial [19].
We believe that the thorough work-up of a case like ours could 
help to better understand the aetiology and the management of 
a bleeding diathesis in patients with lymphoproliferative disease 
under Ibrutinib, and thus, help to better define possible therapeutic 
strategies.
Acknowlegments
We thank Julia Engels and Michael Nagler for valuable 
comments. We also thank the Department of Hematology and Center 
of Laboratory Medicine (ZLM) for the lab analyses. 
Authorship Contributions
SB analyzed data and wrote the paper; UN contributed vital 
material, had the idea, designed research, analyzed data, and wrote 
parts of the paper.
References
1. Curnow JL, Pasalic EJ, Favaloro. Treatment of von Willebrand Disease. 
Semin Thromb Hemost. 2016; 42: 133-146.
2. Federici AB. Acquired von Willebrand syndrome: data from an international 
registry. Thromb Haemost. 2000; 84: 345-349.
3. Tiede A. How I treat the acquired von Willebrand syndrome. Blood. 2011; 
117: 6777-6785.
4. Mohri H. Acquired von Willebrand syndrome: features and management. Am 
J Hematol, 2006; 81: 616-623.
5. Mital A. Acquired von Willebrand Syndrome. Adv Clin Exp Med. 2016; 25: 
1337-1344.
6. Burger JA. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic 
Leukemia. N Engl J Med. 2015; 373: 2425-2437.
7. Khan WN. Defective B cell development and function in Btk-deficient mice. 
Immunity. 1995; 3: 283-299.
8. Wang ML. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell 
lymphoma. N Engl J Med. 2013; 369: 507-516.
9. Byrd JC. Targeting BTK with ibrutinib in relapsed chronic lymphocytic 
leukemia. N Engl J Med. 2013. 369: 32-42.
vWF ACT% vWF AG% FV111%
During Ibrutinib 13 Months 35 44 49
14 Months 16 25 18
1 h after 3000 E 
Haemate 72 185 87
5 h after Haemate 18 93 77
24 h after Haemate 11 55 92
After Ibrutinib 16 25 18
During Idealisib 19 35 39
Table 1: Results of hemostasis test during the treatment in the CLL patients.
Ann Hematol Oncol 7(3): id1290 (2020)  - Page - 03
Bürki S Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
10. Cinar M. Bruton tyrosine kinase is commonly overexpressed in mantle cell 
lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013; 
37: 1271-1277.
11. Hallek M. The HELIOS trial protocol: a phase III study of ibrutinib in 
combination with bendamustine and rituximab in relapsed/refractory chronic 
lymphocytic leukemia. Future Oncol. 2015; 11: 51-59.
12. de Weerdt. Incidence and management of toxicity associated with ibrutinib 
and idelalisib: a practical approach. Haematologica. 2017; 102: 1629-1639.
13. Byrd JC. Ibrutinib versus ofatumumab in previously treated chronic lymphoid 
leukemia. N Engl J Med. 2014; 371: 213-223.
14. Shatzel JJ. Ibrutinib-associated bleeding: pathogenesis, management and 
risk reduction strategies. J Thromb Haemost. 2017; 15: 835-847.
15. Aguilar C. Ibrutinib-related bleeding: pathogenesis, clinical implications and 
management. Blood Coagul Fibrinolysis. 2018; 29: 481-487.
16. Levade M. Ibrutinib treatment affects collagen and von Willebrand factor-
dependent platelet functions. Blood. 2014; 124: 3991-3995.
17. Liu J. Bruton tyrosine kinase is essential for botrocetin/vWF-induced signaling 
and GPIb-dependent thrombus formation in vivo. Blood. 2006; 108: 2596-
2603.
18. Reda G. Idelalisib rapidly improves platelet function tests in patients with 
chronic lymphocytic leukemia. Br J Haematol, 2018; 183: 825-828.
19. Mohri H. Clinical significance of inhibitors in acquired von Willebrand 
syndrome. Blood. 1998; 91: 3623-3629.
